tiprankstipranks
Trending News
More News >
ProAssurance Corporation (PRA)
NYSE:PRA
Advertisement

ProAssurance (PRA) AI Stock Analysis

Compare
78 Followers

Top Page

PRA

ProAssurance

(NYSE:PRA)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - 4o)
Rating:55Neutral
Price Target:
$24.50
▲(2.25% Upside)
ProAssurance's overall score is primarily influenced by its financial performance, which shows significant challenges in revenue growth and cash flow management. The technical analysis suggests a neutral market sentiment, while the valuation indicates the stock is relatively expensive. The strong balance sheet provides some stability, but improvements in cash flow and operational efficiency are crucial for future growth.
Positive Factors
Strong Balance Sheet
A strong balance sheet with low leverage provides financial stability, enabling the company to withstand market fluctuations and invest in growth opportunities.
Strategic Partnership
The partnership with The Doctors Company enhances scale and capabilities, strengthening market position and offering long-term growth potential in the healthcare insurance sector.
Investment Income
Investment income from premiums provides a significant earnings stream, supporting financial performance and offering resilience against underwriting losses.
Negative Factors
Revenue Decline
Significant revenue decline impacts profitability and operational efficiency, posing challenges to sustaining growth and maintaining competitive advantage.
Cash Flow Issues
Negative cash flows indicate inefficiencies in operations, limiting the company's ability to reinvest in growth and manage financial obligations effectively.
Declining Profit Margins
Declining profit margins suggest pressure on operational efficiency, which could hinder the company's ability to generate sustainable profits over time.

ProAssurance (PRA) vs. SPDR S&P 500 ETF (SPY)

ProAssurance Business Overview & Revenue Model

Company DescriptionProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers' Compensation Insurance, Segregated Portfolio Cell Reinsurance, and Lloyd's Syndicate segments. It offers professional liability insurance for healthcare providers and institutions, and attorneys; liability insurance for medical technology and life sciences risks; and workers' compensation insurance, such as guaranteed cost policies, policyholder dividend policies, retrospectively rated policies, and deductible policies, as well as alternative market solutions that include program design, fronting, claims administration, risk management, SPC rental, asset management, and SPC management services for individual companies, agencies, groups, and associations. The company also participates in Lloyd's of London Syndicate 1729, which underwrites property and casualty insurance, and reinsurance. It markets its products through independent agencies and brokers, as well as an internal sales force. The company was founded in 1976 and is headquartered in Birmingham, Alabama.
How the Company Makes MoneyProAssurance generates revenue primarily through insurance premiums collected from policyholders in its various segments. The company underwrites policies for healthcare providers and organizations, charging premiums based on the assessed risk associated with each insured party. Additionally, ProAssurance earns investment income from its portfolio of invested premiums, which is a significant contributor to its overall earnings. The company also benefits from reinsurance agreements that help manage risk exposure and stabilize financial performance. Strategic partnerships with healthcare associations and professional organizations enhance its market reach and credibility, further supporting its revenue generation.

ProAssurance Earnings Call Summary

Earnings Call Date:Feb 24, 2025
(Q4-2024)
|
% Change Since: |
Next Earnings Date:Feb 23, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant improvements in operating earnings, investment income, and strategic initiatives in both the Specialty P&C and workers' compensation segments. However, these positives were counterbalanced by challenges such as the negative impact from Lloyd's Syndicate losses, a decline in net written premiums, and increased expense ratios. While the company showed steady progress in its core operations, some financial setbacks were noted.
Q4-2024 Updates
Positive Updates
Improved Operating Earnings
ProAssurance reported its fifth consecutive quarter of improved operating earnings, highlighting progress in the medical professional liability business.
Specialty P&C Segment Progress
The Specialty P&C segment's full-year combined ratio improved by nearly five points to 104%, with favorable prior accident year reserve development.
Renewal Premium Increases
Renewal premium increases in the fourth quarter were 10% for standard MPL business and 8% for specialty MPL, leading to a cumulative increase of almost 70% since 2018.
Workers' Compensation Segment Initiatives
The workers' compensation segment improved its combined ratio for the quarter and the year, leveraging new systems and AI tools to enhance profitability and efficiency.
Investment Income Growth
Net investment income rose 9% for the quarter and 12% for the year, taking advantage of the rate environment with new purchase yields of approximately 5.8%.
Book Value Per Share Increase
Reported book value per share rose by $1.67 to $23.49, with adjusted book value per share increasing to $26.86.
Negative Updates
Lloyd's Syndicate Loss Impact
A significant fourth-quarter increase in IBNR reserve from aviation risks reduced fourth-quarter net income by $5.3 million, affecting the Specialty P&C segment's combined ratio by about three points.
Decline in Net Written Premiums
Net written premiums declined for both the fourth quarter and full year in the Specialty P&C segment, reflecting disciplined pricing strategies.
Higher Expense Ratios
Increased incentive-based compensation costs led to higher expense ratios in all segments, impacting the overall expense management.
Company Guidance
In the fourth quarter 2024 earnings call, ProAssurance Corporation reported its fifth consecutive quarter of improved operating earnings, highlighting a Specialty P&C segment combined ratio of 101%, improved by nearly nine points from favorable prior accident year reserve development. Full-year 2024 saw a nearly five-point enhancement in the combined ratio to 104%, alongside a 20-point improvement in the accident year loss and LAE ratio since 2019, due to strategic initiatives and premium increases. The company achieved a 10% renewal premium increase in standard MPL and 8% in the specialty portion, bringing cumulative increases since 2018 to nearly 70%. Retention of existing premiums was solid at 83%. In workers' compensation, net written premiums rose by $4 million, with a full-year combined ratio of 114% and a net loss ratio of 77%, reflecting strategic pricing and underwriting efforts. ProAssurance emphasized disciplined underwriting, use of predictive analytics, and investment in innovation tools to maintain a competitive edge, resulting in a full-year operating earnings of $0.95 per share and a reported book value per share increase to $23.49.

ProAssurance Financial Statement Overview

Summary
ProAssurance faces challenges in revenue growth and cash flow management, with declining profitability margins. However, the company maintains a strong balance sheet with low leverage, providing some financial stability. Focus on improving cash flow and operational efficiency is essential for future growth.
Income Statement
45
Neutral
ProAssurance's income statement shows mixed results. The TTM data indicates a decline in revenue growth at -51.2%, which is concerning. Gross profit margin is relatively healthy at 22.45% for the latest annual report, but net profit margin has decreased to 3.03% in the TTM, down from 4.68% in the previous year. EBIT and EBITDA margins have also declined, indicating pressure on operational efficiency.
Balance Sheet
70
Positive
The balance sheet reflects a strong equity position with a low debt-to-equity ratio of 0.0117 in the TTM, significantly reduced from 0.368 in the previous year. Return on equity has decreased to 2.69% in the TTM from 4.39% previously, suggesting reduced profitability. However, the company's high equity ratio indicates financial stability.
Cash Flow
40
Negative
Cash flow analysis reveals challenges, with negative operating and free cash flows in the TTM. The free cash flow growth rate is negative at -53.19%, indicating cash flow issues. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income to cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.10B1.13B1.13B1.10B1.08B886.86M
Gross Profit246.51M253.34M195.11M191.86M212.58M114.85M
EBITDA79.94M103.17M10.02M52.22M203.57M-180.18M
Net Income33.71M52.74M-38.60M-402.00K144.12M-175.73M
Balance Sheet
Total Assets5.55B5.57B5.63B5.70B6.19B4.65B
Cash, Cash Equivalents and Short-Term Investments4.02B3.89B65.90M3.75B4.19B3.01B
Total Debt436.84M442.26M444.31M446.99M445.83M304.83M
Total Liabilities4.25B4.37B4.52B4.60B4.76B3.31B
Stockholders Equity1.30B1.20B1.11B1.10B1.43B1.35B
Cash Flow
Free Cash Flow-18.23M-19.73M-54.67M-34.19M70.13M84.86M
Operating Cash Flow-12.71M-10.71M-49.88M-29.84M73.97M92.34M
Investing Cash Flow37.26M10.67M141.14M-62.00M-85.53M-8.48M
Financing Cash Flow-15.39M-10.97M-55.31M-21.80M-60.62M-43.45M

ProAssurance Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price23.96
Price Trends
50DMA
24.02
Negative
100DMA
23.92
Positive
200DMA
22.67
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
42.87
Neutral
STOCH
35.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRA, the sentiment is Neutral. The current price of 23.96 is below the 20-day moving average (MA) of 24.02, below the 50-day MA of 24.02, and above the 200-day MA of 22.67, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.87 is Neutral, neither overbought nor oversold. The STOCH value of 35.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRA.

ProAssurance Risk Analysis

ProAssurance disclosed 36 risk factors in its most recent earnings report. ProAssurance reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ProAssurance Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$927.19M8.5713.21%1.73%12.22%120.73%
75
Outperform
$1.13B12.919.97%4.79%13.35%16.56%
74
Outperform
$918.88M7.7327.34%2.29%4.61%73.40%
68
Neutral
$576.89M6.8329.35%16.34%-1.26%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
62
Neutral
$709.28M8.1915.10%3.59%0.93%224.95%
55
Neutral
$1.24B36.722.66%-3.35%-21.82%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRA
ProAssurance
23.93
7.18
42.87%
DGICA
Donegal Group
19.87
3.96
24.89%
SAFT
Safety Insurance Group
75.96
-6.13
-7.47%
UFCS
United Fire Group
36.34
5.96
19.62%
UVE
Universal Insurance Holdings
32.61
10.64
48.43%
ACIC
American Coastal Insurance
12.10
-1.68
-12.19%

ProAssurance Corporate Events

ProAssurance Corporation Reports Q3 2025 Earnings
Nov 5, 2025

ProAssurance Corporation is a leading specialty insurer with a focus on medical professional liability and workers’ compensation insurance, operating primarily in the eastern United States.

Financial DisclosuresM&A Transactions
ProAssurance Reports Q3 2025 Financial Results
Neutral
Nov 4, 2025

On November 4, 2025, ProAssurance Corporation reported its financial results for the third quarter of 2025, with a net income of $1.4 million and operating income of $7.9 million. The company continues to make progress in adjusting premium rates to match challenging market conditions. The announcement also highlighted an 8% increase in Specialty P&C renewal premiums and a consolidated Non-GAAP combined ratio of 112.2% for the quarter. ProAssurance is in the process of merging with The Doctors Company, with regulatory approvals pending in several states, and anticipates closing the transaction by June 30, 2026.

The most recent analyst rating on (PRA) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on ProAssurance stock, see the PRA Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 17, 2025